Please login to the form below

Not currently logged in
Email:
Password:

Levest COC promises NHS cost savings

Combined oral contraception, Levest, has won an NHS contract as the preferred drug of its type for hospitals in England

In addition to being listed by the majority of retail pharmacy wholesalers and multiples, Morningside Healthcare's combined oral contraception (COC), Levest, has won an NHS contract as the preferred drug of its type for hospitals in England.

Levest contains levenogesterel 150μg and ethinylestradiol 30μg and costs £2.55 per 63 tablets, or the equivalent of just £0.85 per cycle. This makes it 10 per cent cheaper than competitor, Microgynon 30 (ethinylestradiol and levonorgestrel), which costs £2.82 per 63 tablet, or £0.94 per cycle.

With an estimated one million women in England currently prescribed Microgynon, the potential cost savings for the NHS in England are in excess of £1m a year.

Dr Al-Azzawi, consultant gynaecologist, comments: "The clinical data demonstrates that Levest is bioequivalent to Microgynon 30 and can be prescribed in place of it without any loss of contraceptive efficacy."

5th May 2010

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics